About Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2
Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 (B3GAT2) is a protein
from Homo sapiens identified by UniProt accession
Q9NPZ5, 323 residues long.
MolForge cross-references it against 0 known binders and
120 disease associations.
Target properties
| Protein name | Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 |
|---|
| UniProt accession | Q9NPZ5 |
|---|
| Gene | B3GAT2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 323 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (120)
Diseases linked to this target (Open Targets).
- PHF-tau measurement · score 0.31
- heel bone mineral density · score 0.27
- metabolite measurement · score 0.10
- medulloblastoma · score 0.02
- type 2 diabetes mellitus · score 0.02
- ovarian carcinoma · score 0.02
- Crigler-Najjar syndrome · score 0.02
- Barrett's esophagus · score 0.01
- sickle cell anemia · score 0.01
- colitis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NPZ5-F1 | alphafold | PREDICTED | 85.68 | — |
Amino-acid sequence (323 residues)
MKSALFTRFF ILLPWILIVI IMLDVDTRRP VPPLTPRPYF SPYAVGRGGA RLPLRRGGPA HGTQKRNQSR PQPQPEPQLP TIYAITPTYS RPVQKAELTR LANTFRQVAQ LHWILVEDAA ARSELVSRFL ARAGLPSTHL HVPTPRRYKR PGLPRATEQR NAGLAWLRQR HQHQRAQPGV LFFADDDNTY SLELFQEMRT TRKVSVWPVG LVGGRRYERP LVENGKVVGW YTGWRADRPF AIDMAGFAVS LQVILSNPKA VFKRRGSQPG MQESDFLKQI TTVEELEPKA NNCTKVLVWH TRTEKVNLAN EPKYHLDTVK IEV
Explore Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets